WO2002083174A1 - Method of administering substance to left ventricle - Google Patents

Method of administering substance to left ventricle Download PDF

Info

Publication number
WO2002083174A1
WO2002083174A1 PCT/JP2002/003534 JP0203534W WO02083174A1 WO 2002083174 A1 WO2002083174 A1 WO 2002083174A1 JP 0203534 W JP0203534 W JP 0203534W WO 02083174 A1 WO02083174 A1 WO 02083174A1
Authority
WO
WIPO (PCT)
Prior art keywords
left ventricle
substance
administering
administering substance
function
Prior art date
Application number
PCT/JP2002/003534
Other languages
French (fr)
Japanese (ja)
Inventor
Atsushi Nishimura
Nobuyuki Koyama
Toshifumi Watanabe
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Publication of WO2002083174A1 publication Critical patent/WO2002083174A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

By administering a substance into the left ventricle while substantially narrowing nonhuman mammalian aorta, the substance can be conveniently and efficiently administered to the mammal specifically to the heart. Thus, this administration method is usable in clarifying the function of a gene having an unknown function, screening a candidate compound for a drug, evaluating a drug effect and so on.
PCT/JP2002/003534 2001-04-10 2002-04-09 Method of administering substance to left ventricle WO2002083174A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-110990 2001-04-10
JP2001110990 2001-04-10
JP2002-009142 2002-01-17
JP2002009142 2002-01-17

Publications (1)

Publication Number Publication Date
WO2002083174A1 true WO2002083174A1 (en) 2002-10-24

Family

ID=26613345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/003534 WO2002083174A1 (en) 2001-04-10 2002-04-09 Method of administering substance to left ventricle

Country Status (1)

Country Link
WO (1) WO2002083174A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0970289A (en) * 1995-06-27 1997-03-18 Takeda Chem Ind Ltd Human crf2 recepter protein, its production and use
WO1999046277A1 (en) * 1998-03-09 1999-09-16 Smithkline Beecham Corporation HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0970289A (en) * 1995-06-27 1997-03-18 Takeda Chem Ind Ltd Human crf2 recepter protein, its production and use
WO1999046277A1 (en) * 1998-03-09 1999-09-16 Smithkline Beecham Corporation HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
HARADA K. ET AL.: "Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction", CIRCULATION, vol. 100, 1999, pages 2093 - 2099, XP002952983 *
JEYASEELAN R. ET AL.: "A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes", J. BIOL. CHEM., vol. 272, no. 36, 1997, pages 22800 - 22808, XP002952981 *
KUWAHARA K. ET AL.: "Involvement of cardiotrophin-1 in cardiac myocyte-nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro", CIRCULATION, vol. 100, 1999, pages 1116 - 1124, XP002952980 *
MCVEY M.J. ET AL.: "Cardiovascular pharmacology of the adenosine A1/A2-receptor agonist AMP 579: Coronary hemodynamic and cardioprotective effects in the canine myocardium", J. CARDIOVASC. PHARMACOL., vol. 33, no. 5, 1999, pages 703 - 710, XP002952984 *
MIYAMOTO M.I. ET AL.: "Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure", PROC. NATL. ACAD. SCI. USA, vol. 97, no. 2, 2000, pages 793 - 798, XP002952979 *
MOCHIZUKI S. ET AL.: "Na+/Ca++ exchanger and myocardial ischemia/reperfusion", JPN. HEART J., vol. 39, 1998, pages 707 - 714, XP002952985 *
SHINMURA K. ET AL.: "Catheter-delivered in vivo gene transfer into rat myocardium using the fusigenic liposomal mediated method", JPN. HEART J., vol. 41, 2000, pages 633 - 647, XP002952978 *
ZOU Y. ET AL.: "CARP, a cardiac ankyrin repeat protein, is downstream in the Nkx2-5 homeobox gene pathway", DEVELOPMENT, vol. 124, 1997, pages 793 - 804, XP002952982 *

Similar Documents

Publication Publication Date Title
CN102302493B (en) The method of activation of progenitor cells/stem cell
Yang et al. Mechanisms of the beneficial effect of adrenomedullin and adrenomedullin-binding protein-1 in sepsis: down-regulation of proinflammatory cytokines
ATE442851T1 (en) 1-DEOXY-GALACTONOJIRIMYCIN DERIVATIVES FOR USE IN THE TREATMENT OF LYSOSOMAL STORAGE DISEASES BY BOOSTING LYSOSOMAL ALPHA GALACTOSIDASE A
WO2005012485A3 (en) Methods for treating diabetes and related disorders using pde10a inhibitors
WO2008027272A3 (en) Isolating cardiac circulation
IL148613A0 (en) Methods and compositions for detecting pathological events
WO2002015920A3 (en) Treatment of hyperproliferative diseases
WO2002055721A3 (en) Modular transfection systems based on nucleoprotein filaments
US7659249B2 (en) Membrane-permeable NFAT inhibitory peptide
FOWLER et al. Potentiation of smooth muscle contraction by adrenal steroids
RU2769446C1 (en) Use of chiglitazar and related compounds
SE9501991D0 (en) Preparations for the diagnosis of the metabolic syndrome and in this included disease state
Calnan et al. Potency and stability of C terminal truncated human epidermal growth factor
Fuchs et al. The stimulation of dopa decarboxylase activity by ecdysone and its enhancement by cyclic AMP in adult mosquitoes
WO2002083174A1 (en) Method of administering substance to left ventricle
Dzemeshkevich et al. Plasmapheresis in the treatment of posttransplant cardiomyopathy
Wang et al. Advanced donor age impairs bone marrow cell therapeutic efficacy for cardiac disease
US7423009B2 (en) Method for treatment of kidney diseases
WO2001048164A3 (en) Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure
Zhu et al. Exchange proteins directly activated by cAMP mediate cardiac repolarization and arrhythmogenesis during chronic heart failure
EP0313005A3 (en) Method for detecting carcinomatous and precarcinomatous colo-rectal disease
Cornford et al. Schistosoma mansoni, S. japonicum, S. haematobium: Glycogen content and glucose uptake in parasites from fasted and control hosts
Yorgey et al. Evaluation of drug absorption and presystemic metabolism using an in situ intestinal preparation
Matijatko et al. Serum cor tisol and insulin concentrations in dogs naturally infected Serum cor tisol and insulin concentrations in dogs naturally infected with Babesia canis
CN101327221A (en) Medical use of Ophiopogon root saponin D as tissue factor pathway inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP